General Surgery Coding Alert - 2005 Issue 29
PHARMACEUTICALS: CAP Vendors-Too Much Trouble?
Subscribe or sign in to view the full article.
Article Overview
This article examines commentary from physicians and practice leaders about CMS’s Competitive Acquisition Program for Part B drugs and the practical concerns surrounding vendor participation. It focuses on administrative burden, patient access concerns, and operational issues that may affect oncology and urology practices. The piece is relevant to physicians, practice managers, and reimbursement staff evaluating whether the program is worth the effort.
Why This Topic Matters
It highlights how policy changes in drug acquisition and vendor management can affect office workflow, patient treatment continuity, and practice administration.
What You Will Learn
- The main concerns raised by physicians about participating in the CAP for Part B drugs
- How vendor involvement may affect practice operations and patient treatment workflows
- Why some practices question whether the program offers enough benefit to justify its administrative demands
- What kinds of operational issues are discussed in relation to unused or defective medication and copayment problems
Who Should Read This
- Physicians
- Practice managers
- Billing and reimbursement staff
- Oncology practices
- Urology practices
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com